Recent Finacing
Recent Raise
CadheRx develops therapeutic antibodies targeting soluble E-cadherin to treat Cetuximab- and Herceptin-resistant epithelial solid tumors, advancing preclinical in vitro/in vivo candidates from Stony Brook–licensed IP in San Diego.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor